CVS Health and Vertex Pharmaceuticals Outlook
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 26 2026
0mins
Should l Buy CVS?
Source: NASDAQ.COM
- CVS Health Strategic Shift: CVS Health plans to scale back its Medicare Advantage business in 2026, which may not significantly impact financial results in the short term but aims to enhance long-term profitability, thereby strengthening its leadership position in the healthcare sector.
- Stock Price Recovery: In 2025, CVS Health's share price soared over 70% due to improved financial results, laying a solid foundation for continued growth in 2026, reflecting the company's deep roots in the U.S. healthcare ecosystem and strong customer relationships.
- Vertex Pharmaceuticals New Product Progress: Vertex Pharmaceuticals expects its new products, Journavx and Casgevy, to generate at least $500 million in sales in 2026, which, while modest, will provide crucial support for the company's future revenue growth.
- Clinical and Regulatory Advances: Vertex plans to seek approval for its investigational medicine zimislecel for Type 1 diabetes in 2026 and release phase 3 study data for next-gen programs, further enhancing the diversity and competitiveness of its product lineup.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CVS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CVS
Wall Street analysts forecast CVS stock price to rise
17 Analyst Rating
16 Buy
1 Hold
0 Sell
Strong Buy
Current: 78.260
Low
91.00
Averages
96.71
High
105.00
Current: 78.260
Low
91.00
Averages
96.71
High
105.00
About CVS
CVS Health Corporation is a health solutions company. The Company's segments include Health Care Benefits, Health Services, Pharmacy & Consumer Wellness and Corporate/Other. Health Care Benefits segment offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, PDPs and Medicaid health care management services. Health Services segment provides a full range of pharmacy benefit management (PBM) solutions through its CVS Caremark operations and delivers health care services in its medical clinics, virtually, and in the home. Pharmacy & Consumer Wellness segment dispenses prescriptions in its CVS Pharmacy retail locations and through its infusion operations, provides ancillary pharmacy services including pharmacy patient care programs, diagnostic testing and vaccination administration, and sells a wide assortment of health and wellness products and general merchandise.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Technical Signal Warning: Amazon's stock is nearing a death cross signal, where the 50-day moving average falls below the 200-day average, typically indicating short-term bearish sentiment and reflecting market reassessment of its valuations after months of volatility.
- Debt Financing Strategy: Despite the short-term technical warning, Amazon is aggressively tapping debt markets to fund AI infrastructure, cloud computing expansion, and logistics investments, showcasing its long-term ambitions in the evolving tech landscape.
- Capital-Intensive Transformation: The bond offering signifies a shift in Big Tech from relatively asset-light software platforms to capital-heavy infrastructure builders for the AI era, indicating a significant transformation in corporate balance sheets across the sector.
- Market Tension: The looming death cross juxtaposed with one of the largest bond sales in years highlights the tension between short-term technical caution and long-term AI optimism, suggesting that investors should closely monitor these market dynamics.
See More
- Price Fluctuation Analysis: VHT's 52-week low is $234.11 and high is $298.6068, with the current trading price at $280.49, indicating significant price movement that may influence investor buying decisions.
- Technical Analysis Tool: Comparing the current stock price to the 200-day moving average provides investors with deeper insights into market trends and potential buying opportunities, enhancing their trading strategies.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) operate similarly to stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding for ETFs helps identify those experiencing notable inflows or outflows, allowing investors to assess the impact on underlying assets and make informed investment decisions.
See More
- Weak Job Market: The U.S. nonfarm payrolls unexpectedly fell by 92,000 in February, significantly below the forecast of 50,000 and down from the revised January total of 126,000, indicating ongoing economic pressure from severe winter weather and a strike in the healthcare sector.
- Rising Unemployment Rate: The unemployment rate increased to 4.4%, reflecting job losses across key sectors, although a broader measure of unemployment, which includes discouraged workers and part-time workers for economic reasons, decreased to 7.9%, suggesting some resilience in the labor market.
- Wage Growth Exceeds Expectations: Despite the weak job data, average hourly earnings rose by 0.4% for the month and 3.8% year-over-year, both exceeding forecasts by 0.1 percentage points, indicating persistent labor cost pressures that could influence future monetary policy decisions.
- Significant Industry Impact: The healthcare sector lost 28,000 jobs due to the Kaiser Permanente strike, while information services and manufacturing saw declines of 11,000 and 12,000 jobs respectively, highlighting structural challenges within industries that may lead policymakers to adopt a more cautious approach in response to economic slowdown.
See More
- Health Tech Innovation: CVS Health announced the launch of Health100, a health-tech services unit leveraging Google Cloud's AI technologies aimed at enhancing consumer engagement and improving health outcomes, with an initial rollout planned for this year.
- Personalized Experience: Health100 will provide patients with a personalized experience regardless of their chosen pharmacy, healthcare provider, health insurer, or pharmacy benefits manager, thereby empowering customers in their health management and fostering trust and better health outcomes.
- Technology Support: The platform will utilize Google Cloud's AI technologies, including Gemini models, Cloud Healthcare API, and BigQuery, ensuring efficient data processing and analysis to enhance user experience and service quality.
- Vision for Future Healthcare: CVS executives stated that Health100 represents the future of intelligent healthcare, aiming to enhance patient health management experiences by improving human touch and simplifying complexities, marking a significant step towards digital transformation in the healthcare industry.
See More
- Strategic Partnership Launch: CVS Health and Google Cloud have announced a strategic partnership aimed at reimagining healthcare experiences through the launch of the Health100 platform, which will enhance consumer engagement and ultimately support better health outcomes.
- Health100 Platform Features: The platform will leverage built-in agentic AI to provide a real-time, omni-channel experience, enabling consumers to take full ownership of their health, offering proactive support to achieve better health goals while simplifying healthcare processes and reducing financial burdens.
- Technology Support Assurance: Health100 will be supported by Google Cloud's secure, enterprise-ready platform and AI technologies, including Gemini models and Cloud Healthcare API, ensuring the security and privacy of patient data while enhancing user control over their information.
- Future Development Plans: Health100 is set to launch in 2026 and will allow other health innovators to build specialized applications as part of an open ecosystem, further driving the digital transformation of the healthcare industry.
See More

Partnership Announcement: CVS Health and Google Cloud have formed a strategic partnership aimed at enhancing health care consumer engagement and experiences.
Focus on Consumer Engagement: The collaboration will leverage technology to improve how consumers interact with health care services, aiming to create more personalized and efficient experiences.
See More









